Skip to main content
Neil Shusterman, MD, Nephrology, Haverford, PA

NeilHowardShustermanMD(He/Him)

Nephrology • Haverford, PA

Independent Consultant

Join to view full profile

Dr. Shusterman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shusterman's full profile

Already have an account?

  • Office

    255 VALLEY RIDGE RD
    Haverford, PA 19041

Summary

  • Dr. Neil Shusterman specializes in Nephrology and is based in Haverford, PA. He completed his medical degree at Sidney Kimmel Medical College at Thomas Jefferson University in 1978 and pursued his residency in Internal Medicine at Main Line Health System/Lankenau Medical Center. He further advanced his specialization with a Fellowship in Nephrology at University of Pennsylvania Health System from 1981-1983. Currently, Dr. Shusterman holds the position of Clinical Drug Development Consultant at NHSMD Clinical Consulting LLC. He is an established author, having published research in several esteemed medical journals including Dermatologic Surgery, Clinical Drug Investigation, Ann Intern Med, Expert Opinion on Drug Safety, and American Heart Journal.

Education & Training

  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemFellowship, Nephrology, 1981 - 1983
  • Main Line Health System/Lankenau Medical Center
    Main Line Health System/Lankenau Medical CenterResidency, Internal Medicine, 1978 - 1981
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1978

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1979 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Nephrology

Publications & Presentations

PubMed

Authored Content

  • The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure — NEJMMay 1996

Press Mentions

  • Palladio Biosciences Announces First Patient Dosed with Lixivaptan in the ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued from Treatment with Tolvaptan Due to Liver Toxicity
    Palladio Biosciences Announces First Patient Dosed with Lixivaptan in the ALERT Study, a Phase 3 Study of ADPKD Patients Previously Discontinued from Treatment with Tolvaptan Due to Liver ToxicityNovember 17th, 2020
  • Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient Who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 Meeting
    Palladio Biosciences Announces Presentation of Data from a Study of Lixivaptan Use in an ADPKD Patient Who Previously Experienced Liver Toxicity with Tolvaptan During the American Society of Nephrology Kidney Week 2020 MeetingOctober 20th, 2020
  • Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief Medical Officer (CMO)
    Palladio Biosciences Appoints Neil H. Shusterman, M.D., as Chief Medical Officer (CMO)January 3rd, 2019

Dr. Neil Shusterman, Dr. Neil Shusterman, MD, Dr. N Shusterman, Dr. Neil Howard Shusterman